FIAT CHRYSLER AUTOMOBILES N.V.: JANUARY 2017 FIAT CHRYSLER

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
116
FIAT CHRYSLER AUTOMOBILES N.V.: JANUARY 2017 FIAT CHRYSLER AUTOMOBILES SALES IN EUROPE

In January, FCA sales in Europe were up 15.2% year-over-year, once again outperforming the industry average of 10.1%. Group market share increased to 7.0% from 6.6% one year ago. January sales were up 31.4% for Alfa Romeo, 17.3% for Fiat and 2.5% for Lancia. The Fiat Panda and Fiat 500 continued their leadership in the European A segment with a combined 31.6% share. The Fiat 500L was the best selling vehicle in its segment with a share of nearly 22%. The Fiat 500X and Jeep Renegade were once again among the leaders in their segment with a combined 12.1% share. The Fiat Tipo, already one of the most popular vehicles in Italy, continues to gain momentum in Europe. 

FCA started the year with another strong monthly sales performance in Europe (EU28+EFTA). Group sales were up 15.2% (+10.1% for the industry) to approximately 83,800 vehicles. Market share was 40 basis points higher at 7.0%. FCA posted increases in nearly all major European markets, with sales up 12.7% in Italy (industry +10.1%), 22.7% in Germany (industry +10.5%), 19.0% in France (industry +10.6%) and 32.2% in Spain (industry +10.6%).

Fiat brand posted a 17.3% increase in European sales in January, with 63,500 vehicles sold. Market share was 40 basis points higher at 5.3%. The brand posted increases of 14.5% in Italy, 25.0% in Germany, 24.1% in France, 41.6% in Spain, 31.4% in Switzerland, 20.1% in Austria, 22.3% in Belgium, 19.9% in the Netherlands and 107.5% in Poland. Fiat remained leader in the European A segment with the Panda and 500 holding a combined 31.6% share. The Panda was overall leader with approximately 17,900 units sold (+4.8% year-over-year) followed by the 500 with approximately 15,700 units sold (+14.6%). The 500L was leader in the Small MPV segment with a nearly 22.0% share. The 500X continued as one of the best selling models in the Small SUV segment, ranking first in Italy with a 14.7% share, and among the top 5 in Spain, Belgium and Austria. The Fiat Tipo continued to gain momentum, ranking second in its segment in Italy and posting sales increases across Europe.

Lancia/Chrysler posted January sales of nearly 5,900 vehicles (+2.5% year-over-year). Share was in line with the prior year at 0.5%. Sales of the Lancia Ypsilon were up 2.8% year-over-year in Europe and 4.0% in Italy, where it is leader in the B segment. 

Alfa Romeo posted another strong month with a significant contribution from the Giulia. In fact, sales were up 31.4% year-over-year, with a total of 6,000 vehicles sold, and market share was 10 basis points higher at 0.5%. Sales were up 27.2% in Italy, 48.4% in Germany, 2.4% in France and 58.6% in Spain.

Jeep brand sales in Europe totaled 7,400 vehicles and market share was 0.6%. Sales in France were up 1.5%. The Jeep Renegade, consistently one of the top ten in its segment, made another solid contribution with sales up 0.8% year-over-year.

For Maserati , the Group's luxury brand, European sales in January totaled 995 vehicles.

London, 16 February 2017

For further information: +39.011.0063088 mediarelations@fcagroup.com www.fcagroup.com

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...d492a04e5c

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading